Clinical trials: Mycophenolate Mofetil
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00425802
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphoid System Neoplasm
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant.
- Trial name
- NCT04022239
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Transplant Rejection, Renal Transplant Infection
NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation
Kidney transplantation provides the optimal form of kidney replacement therapy for the majority of people with end-stage kidney disease, and has now become the commonest form of kidney replacement therapy.
- Trial name
- NCT05073822
- Testing
- Tacrolimus
- Sponsor
- University College, London
Renal Transplantation
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
The study is designed to evaluate whether the initiation of everolimus together with the reduction or discontinuation of calcineurin inhibitors (CNIs) will improve graft function in the maintenance of renal transplant recipients…
- Trial name
- NCT00170846
- Testing
- Everolimus (RAD001), Calcineurin Inhibitors (CNI), Mycophenolate acid (MPA)/Azathioprine (AZA)
- Where
- Switzerland
- Volunteers
- 394 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.
- Trial name
- DIAMOND (NCT01011205)
- Testing
- Advagraf, Mycophenolate Mofetil, Basiliximab
- Where
- 72 sites in Argentina, Austria and 21 more
- Volunteers
- 893 people
- Sponsor
- Astellas Pharma Inc
Systemic Sclerosis
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either…
- Trial name
- NCT03844061
- Testing
- Belimumab, Rituximab, MMF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hospital for Special Surgery, New York
Malignant Neoplasm
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant works in treating patients with hematologic malignancies.
- Trial name
- NCT01871441
- Testing
- Total-body irradiation, Donor lymphocytes infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Refractory or Relapsed Lymphoid Haemopathy
Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in lymphoid hematological refractory or multiple relapses after chemotherapy.
- Trial name
- LY-SET-HAPLO (NCT03079089)
- Testing
- Sequential Packaging (SET), Transfusion graft, Prevention of GVHD
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Kidney Transplantation
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection…
- Trial name
- NCT00885820
- Testing
- Tacrolimus, MMF, Corticosteroids (Prednisone)
- Where
- 12 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Inc
Haematologic Disease
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation
For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies.
- Trial name
- CTL-DP 01 (NCT04180059)
- Testing
- CTL 19
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Nantes University Hospital
Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Childhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement.
- Trial name
- LIGHT (NCT07719140)
- Testing
- High-dose prednisone, Low-dose prednisone
- Where
- 8 sites in China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital
Hepatitis, Autoimmune, Primary Biliary Cholangitis
Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy
Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by mycophenolate mofetil versus cyclosporin A
- Conditions
- Hepatitis, Autoimmune, Primary Biliary Cholangitis, Immunosuppression
- Trial name
- NCT04376528
- Testing
- Cyclosporin A, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 89 people
- Sponsor
- West China Hospital
Kidney Transplantation
An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients
This observational survey study will capture all renal transplant patients in Serbia who are currently receiving CellCept (mycophenolate mofetil) as part of their immunosuppressive protocol.
- Trial name
- NCT01707550
- Where
- 3 sites in Serbia
- Volunteers
- 414 people
- Sponsor
- Hoffmann-La Roche
Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
The purpose of this study is to compare the incidences of GVHD and viral infections in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (ATG) for acute…
- Conditions
- Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin, Viral Infection
- Trial name
- NCT01883180
- Testing
- ATG
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Transplantation
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients
This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo liver transplantation.
- Trial name
- NCT01128335
- Testing
- MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
- Where
- 39 sites in United States, Argentina and 10 more
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor.
- Conditions
- Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- PTBCy (NCT04943757)
- Testing
- Bendamustine Hydrochloride, Cyclophosphamid
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Healthy
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
- Trial name
- NCT05202145
- Testing
- ALXN2050, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.